Behaviour Hallmarks in Alzheimer's Disease 5xFAD Mouse Model

被引:11
|
作者
Padua, Mafalda Soares [1 ,2 ]
Guil-Guerrero, Jose L. [3 ]
Lopes, Paula Alexandra [1 ,2 ]
机构
[1] Univ Lisbon, Fac Med Vet, CIISA Ctr Invest Interdisciplinar Sanidade Anim, P-1300477 Lisbon, Portugal
[2] Univ Lisbon, Fac Med Vet, Lab Associado Ciencia Anim & Vet AL4AnimalS, P-1300477 Lisbon, Portugal
[3] Univ Almeria, Dept Tecnol Alimentos, Almeria 04120, Spain
关键词
Alzheimer's disease; transgenic mice; 5xFAD model; behaviour; cognitive decline; sensorial impairment; PREVENTS SYNAPTIC LOSS; MEMORY DEFICITS; PSYCHOLOGICAL SYMPTOMS; COGNITIVE DEFICITS; NEURON LOSS; MICE; IMPAIRMENT; DISORDERS; NEURODEGENERATION; IDENTIFICATION;
D O I
10.3390/ijms25126766
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The 5xFAD transgenic mouse model widely used in Alzheimer's disease (AD) research recapitulates many AD-related phenotypes with a relatively early onset and aggressive age-dependent progression. Besides developing amyloid peptide deposits alongside neuroinflammation by the age of 2 months, as well as exhibiting neuronal decline by the age of 4 months that intensifies by the age of 9 months, these mice manifest a broad spectrum of behavioural impairments. In this review, we present the extensive repertoire of behavioural dysfunctions in 5xFAD mice, organised into four categories: motor skills, sensory function, learning and memory abilities, and neuropsychiatric-like symptoms. The motor problems, associated with agility and reflex movements, as well as balance and coordination, and skeletal muscle function, typically arise by the time mice reach 9 months of age. The sensory function (such as taste, smell, hearing, and vision) starts to deteriorate when amyloid peptide buildups and neuroinflammation spread into related anatomical structures. The cognitive functions, encompassing learning and memory abilities, such as visual recognition, associative, spatial working, reference learning, and memory show signs of decline from 4 to 6 months of age. Concerning neuropsychiatric-like symptoms, comprising apathy, anxiety and depression, and the willingness for exploratory behaviour, it is believed that motivational changes emerge by approximately 6 months of age. Unfortunately, numerous studies from different laboratories are often contradictory on the conclusions drawn and the identification of onset age, making preclinical studies in rodent models not easily translatable to humans. This variability is likely due to a range of factors associated with animals themselves, housing and husbandry conditions, and experimental settings. In the forthcoming studies, greater clarity in experimental details when conducting behavioural testing in 5xFAD transgenic mice could minimise the inconsistencies and could ensure the reliability and the reproducibility of the results.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Effects of streptozocin-induced diabetes on behaviour in a 5XFAD mouse model of Alzheimer's disease
    Sonn, K.
    Zharkovsky, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S535 - S536
  • [2] Retinal and thalamic alterations in the 5xFAD mouse model of Alzheimer's disease
    Mccool, Shaylah
    Smith, Jennie C.
    Sladek, Asia
    Fan, Shan
    Van Hook, Matthew J.
    PLOS ONE, 2025, 20 (03):
  • [3] Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer's disease
    Forner, Stefania
    Kawauchi, Shimako
    Balderrama-Gutierrez, Gabriela
    Kramar, Eniko A.
    Matheos, Dina P.
    Phan, Jimmy
    Javonillo, Dominic, I
    Tran, Kristine M.
    Hingco, Edna
    da Cunha, Celia
    Rezaie, Narges
    Alcantara, Joshua A.
    Baglietto-Vargas, David
    Jansen, Camden
    Neumann, Jonathan
    Wood, Marcelo A.
    MacGregor, Grant R.
    Mortazavi, Ali
    Tenner, Andrea J.
    LaFerla, Frank M.
    Green, Kim N.
    SCIENTIFIC DATA, 2021, 8 (01)
  • [4] Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer’s disease
    Stefania Forner
    Shimako Kawauchi
    Gabriela Balderrama-Gutierrez
    Enikö A. Kramár
    Dina P. Matheos
    Jimmy Phan
    Dominic I. Javonillo
    Kristine M. Tran
    Edna Hingco
    Celia da Cunha
    Narges Rezaie
    Joshua A. Alcantara
    David Baglietto-Vargas
    Camden Jansen
    Jonathan Neumann
    Marcelo A. Wood
    Grant R. MacGregor
    Ali Mortazavi
    Andrea J. Tenner
    Frank M. LaFerla
    Kim N. Green
    Scientific Data, 8
  • [5] Bezafibrate confers neuroprotection in the 5xFAD mouse model of Alzheimer's disease
    Lu, Yubing
    Fujioka, Hisashi
    Wang, Wenzhang
    Zhu, Xiongwei
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2023, 1869 (08):
  • [6] Latency to startle is reduced in the 5xFAD mouse model of Alzheimer's disease
    Story, Darren
    Chan, Emily
    Munro, Nikolas
    Rossignol, Julien
    Dunbar, Gary L.
    BEHAVIOURAL BRAIN RESEARCH, 2019, 359 : 823 - 827
  • [7] Retinal hyperspectral imaging in the 5xFAD mouse model of Alzheimer’s disease
    Jeremiah K. H. Lim
    Qiao-Xin Li
    Tim Ryan
    Phillip Bedggood
    Andrew Metha
    Algis J. Vingrys
    Bang V. Bui
    Christine T. O. Nguyen
    Scientific Reports, 11
  • [8] Early Mitochondrial Defects in the 5xFAD Mouse Model of Alzheimer's Disease
    Sharma, Neelam
    Banerjee, Rupkatha
    Davis, Ronald L.
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 90 (04) : 1323 - 1338
  • [9] Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model
    Jeong, Ye Ji
    Son, Yeonghoon
    Park, Hye-Jin
    Oh, Se Jong
    Choi, Jae Yong
    Ko, Young-Gyu
    Lee, Hae-June
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (17)
  • [10] Cognition and hippocampal plasticity in 5XFAD mouse model of Alzheimer's disease
    Sonn, K.
    Jaako, K.
    Jain, R. K.
    Zharkovsky, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S550 - S550